Staley BS, Robinson LR, Claussen AH, Katz SM, Danielson ML, Summers AD, et al. Attention-Deficit/Hyperactivity disorder diagnosis, treatment, and telehealth use in adults - National Center for Health Statistics rapid surveys system, United States, October-November 2023. MMWR Morb Mortal Wkly Rep. 2024;73:890–5.

Article  PubMed  PubMed Central  Google Scholar 

Danielson ML, Claussen AH, Bitsko RH, Katz SM, Newsome K, Blumberg SJ, et al. ADHD prevalence among U.S. children and adolescents in 2022: diagnosis, severity, co-occurring disorders, and treatment. J Clin Child Adolesc Psychol. 2024;53:343–60.

Article  PubMed  PubMed Central  Google Scholar 

Jaeschke RR, Sujkowska E, Sowa-Kućma M. Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review. Psychopharmacology (Berl). 2021;238:2667–91.

Article  CAS  PubMed  Google Scholar 

Patrick KS, Kilts CD, Breese GR. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem. 1981;24:1237–40.

Article  CAS  PubMed  Google Scholar 

Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet. 2003;42:393–401.

Article  CAS  PubMed  Google Scholar 

Childress AC, Komolova M, Sallee FR. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. Expert Opin Drug Metab Toxicol. 2019;15:937–74.

Article  CAS  PubMed  Google Scholar 

LeVasseur NL, Zhu H-J, Markowitz JS, DeVane CL, Patrick KS. Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping. J Chromatogr B Anal Technol Biomed Life Sci. 2008;862:140–9.

Article  CAS  Google Scholar 

Law R, Lewis D, Hain D, Daut R, DelBello MP, Frazier JA, et al. Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in vitro models of hepatic metabolism. Xenobiotica. 2022;52:676–86.

Article  CAS  PubMed  Google Scholar 

Stevens T, Sangkuhl K, Brown JT, Altman RB, Klein TE. PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2019;29:136–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faraj BA, Israili ZH, Perel JM, Jenkins ML, Holtzman SG, Cucinell SA, et al. Metabolism and disposition of methylphenidate-14C: studies in man and animals. J Pharm Exp Ther. 1974;191:535–47.

Article  CAS  Google Scholar 

Dinis-Oliveira RJ. Metabolomics of methylphenidate and ethylphenidate: implications in pharmacological and toxicological effects. Eur J Drug Metab Pharmacokinet. 2017;42:11–6.

Article  CAS  PubMed  Google Scholar 

Egger H, Bartlett F, Dreyfuss R, Karliner J. Metabolism of methylphenidate in dog and rat. Drug Metab Dispos. 1981;9:415–23.

Article  CAS  PubMed  Google Scholar 

Qian Y, Markowitz JS. Natural products as modulators of CES1 activity. Drug Metab Dispos. 2020;48:993–1007.

Article  CAS  PubMed  Google Scholar 

Wang D, Zou L, Jin Q, Hou J, Ge G, Yang L. Human carboxylesterases: a comprehensive review. Acta Pharm Sin B. 2018;8:699–712.

Article  PubMed  PubMed Central  Google Scholar 

Her L, Zhu H-J. Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators. Drug Metab Dispos. 2020;48:230–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu H-J, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharm Exp Ther. 2013;344:665–72.

Article  CAS  Google Scholar 

Zhu H-J, Patrick KS, Yuan H-J, Wang J-S, Donovan JL, DeVane CL, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008;82:1241–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu H-J, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos. 2009;37:264–7.

Article  CAS  PubMed  Google Scholar 

Zhu H-J, Appel DI, Johnson JA, Chavin KD, Markowitz JS. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharm. 2009;77:1266–72.

Article  CAS  PubMed  Google Scholar 

Zhang Q, Melchert PW, Markowitz JS. In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir. Chem Biol Interact. 2022;365:110097.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lewis JP, Horenstein RB, Ryan K, O’Connell JR, Gibson Q, Mitchell BD, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013;23:1–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lewis JP, Ryan KA, Streeten EA, Whitlatch HB, Daue M, Tanner K, et al. Randomized evaluation of the loss-of-function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics. Clin Transl Sci. 2024;17:e70079.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Li J, Zhu H-J. Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review. Expert Opin Drug Metab Toxicol. 2024;20:377–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu H-J, Brinda B, Froehlich TE, Markowitz JS. A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants. Pharmacogenet Genomics. 2012;22:215–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiao J, Shi J, Thompson BR, Smith DE, Zhang T, Zhu H-J. Physiologically-based pharmacokinetic modeling to predict methylphenidate exposure affected by interplay among carboxylesterase 1 pharmacogenetics, drug-drug interactions, and sex. J Pharm Sci. 2022;111:2606–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stage C, Jürgens G, Guski LS, Thomsen R, Bjerre D, Ferrero-Miliani L, et al. The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects. Br J Clin Pharm. 2017;83:1506–14.

Article  CAS  Google Scholar 

Tarkiainen EK, Backman JT, Neuvonen M, Neuvonen PJ, Schwab M, Niemi M. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharm Ther. 2012;92:68–71.

Article  CAS  Google Scholar 

Wang X, Her L, Xiao J, Shi J, Wu AH, Bleske BE, et al. Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Transl Sci. 2021;14:1380–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qian Y, Markowitz JS. Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models. Drug Metab Dispos. 2022;50:968–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patrick KS, Straughn AB, Reeves OT, Bernstein H, Bell GH, Anderson ER, et al. Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans. Drug